[The benefit from ibandronate in the treatment of postmenopausal osteoporosis].
Apart from other factors, the treatment of osteoporosis is limited by a narrow range of applicable drugs. Ibandronate, forming part of the aminobisphosphonate group, which was launched in clinical practice in 2005, has extended the range of treatment options. It allows for intermittent dosage in 1-month (oral form) or 3-month (intravenous form) intervals, whilst the high efficiency of treatment and good safety profile are preserved. Intermittent dosage significantly improves the adherence of patients to treatment, which has, apart from other advantages, a positive effect on cost efficiency of treatment. In addition, oscillation in bone remodelation in the course of intermittent ibandronate treatment might have a positive effect on the physiology of bone tissue, thus reducing some risks associated with bisphosphonate treatment.
Málek
Z
Z
Osteocentrum MEDIEKOS Labor sro Zlín. malek.z@post.cz
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077557:Ibandronic Acid